HLS Therapeutics Inc (HLS)

Currency in CAD
3.65
-0.02(-0.54%)
Closed·
HLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.593.71
52 wk Range
3.515.25
Key Statistics
Prev. Close
3.65
Open
3.67
Day's Range
3.59-3.71
52 wk Range
3.51-5.25
Volume
96.01K
Average Volume (3m)
66.06K
1-Year Change
-27%
Book Value / Share
2.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.38
Upside
+102.23%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

HLS Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.38
(+102.23% Upside)

HLS Therapeutics Inc Earnings Call Summary for Q3/2026

  • HLS Therapeutics Q3 revenue rose 5% YoY to $14.16M but missed estimates by 4.8%; adjusted EPS loss of $0.07 exceeded forecast loss by 14%.
  • Cardiovascular portfolio grew 21% in local currency; NILEMDO added 1,700 patients with sales above CAD 800K, up 91% sequentially from Q2.
  • Company narrowed 2026 adjusted EBITDA guidance to lower half of $18.5M-$21M range, citing launch spending and product mix shift pressures.
  • Management expects revenue and EBITDA acceleration in 2027 driven by NILEMDO reimbursement, potential NEXLIZET launch, and VERQUVO commercialization.
  • Shares fell 9.07% to $3.81 post-earnings, near 52-week low, as legacy Clozaril sales declined 2.6% in Canada while U.S. sales remained flat.
Last Updated: 2026-11-12, 10:26 a/m
Read Full Transcript

Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
-0.07 / -0.06
Revenue / Forecast
14.16M / 14.88M
EPS Revisions
Last 90 days

HLS Income Statement

Compare HLS to Peers and Sector

Metrics to compare
HLS
Peers
Sector
Relationship
P/E Ratio
−11.2x−0.4x−0.2x
PEG Ratio
−0.220.000.00
Price/Book
1.5x0.9x2.6x
Price / LTM Sales
1.3x1.9x2.6x
Upside (Analyst Target)
102.3%76.2%77.0%
Fair Value Upside
Unlock0.3%13.7%Unlock

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda’s Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Employees
85
Market
Canada

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
421.45K1.40%1.54M
Other Institutional Investors
11.40M37.79%41.61M
Public Companies & Retail Investors
18.35M60.81%66.96M
Total
30.17M100.00%110.11M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Stadium Capital Management, LLC19.63%5,922,65821,618
Polar Asset Management Partners Inc.18.16%5,477,86719,994

People Also Watch

23.94
CG
-7.03%
16.18
WCP
-0.98%
125.53
NVDA
-14.01%

FAQ

What Is the HLS Therapeutics (HLS) Stock Price Today?

The HLS Therapeutics stock price today is 3.65 CAD.

What Stock Exchange Does HLS Therapeutics Trade On?

HLS Therapeutics is listed and trades on the Toronto Stock Exchange.

What Is the Stock Symbol for HLS Therapeutics?

The stock symbol for HLS Therapeutics is "HLS."

What Is the HLS Therapeutics Market Cap?

As of today, HLS Therapeutics market cap is 110.11M CAD.

What Is HLS Therapeutics's Earnings Per Share (TTM)?

The HLS Therapeutics EPS (TTM) is -0.31.

When Is the Next HLS Therapeutics Earnings Date?

HLS Therapeutics will release its next earnings report on Mar 18, 2027.

From a Technical Analysis Perspective, Is HLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has HLS Therapeutics Stock Split?

HLS Therapeutics has split 0 times.

How Many Employees Does HLS Therapeutics Have?

HLS Therapeutics has 85 employees.

What is the current trading status of HLS Therapeutics (HLS)?

As of Nov 22, 2026, HLS Therapeutics (HLS) is trading at a price of 3.65 CAD, with a previous close of 3.65 CAD. The stock has fluctuated within a day range of 3.59 CAD to 3.71 CAD, while its 52-week range spans from 3.51 CAD to 5.25 CAD.

What Is HLS Therapeutics (HLS) Price Target According to Analysts?

The average 12-month price target for HLS Therapeutics is 7.38 CAD, with a high estimate of 12.07687894 CAD and a low estimate of 4.27710843 CAD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +102.23% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.